Last reviewed · How we verify

NCT06264622: GARDOSE

ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension

Status unknown NA Last updated 20 February 2024
What this trial tests

NA trial testing Low dose in Hypertension in 180 participants. Status unknown.

Timeline
26 February 2024
Primary endpoint
31 October 2024
31 December 2024

Quick facts

Lead sponsorUniversitat de Lleida
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment180
Start date26 February 2024
Primary completion31 October 2024
Estimated completion31 December 2024
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Universitat de Lleida

Who can join

Adults 18 to 75, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the dose response effect on cardiovascular disease risk factors of a Black Garlic Extract in subjects with Grade I Hypertension. The main questions it aims to answer are: * If the reduction in blood pressure (systolic and diastolic) is in a dose-response manner * If the changes in lipid profile are in a dose-response manner Participants will be randomly assign to a low dose (250 mg/day), high dose (600 mg/day) or placebo of a standardized Garlic Extract (ABG+/GarlACE) during 12 weeks

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Low dose

Trials testing the same drug.

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Universitat de Lleida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06264622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing